Furthermore, an interesting approach based on CCR4 CAR-T cells displayed antigen-dependent potent cytotoxicity against patient-derived cell lines of T-cell lymphoma, thus suggesting the feasibility of such approach also for CCR4-expressing T-ALL patients [184]. This evidence concerns the gene CCR4 and T-cell non-Hodgkin lymphoma.